A director at Argen X SE sold 426 shares at 547.910EUR and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showin...
argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025 August 19, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced it will host a webinar, titled “R&D Spotlight | Pioneering MuSK Biology with ARGX-119” on Tuesday, September 16, 2025, at 2:00pm ET. The webinar will be the first of a ‘mini’ series highlighting the argenx pipeline and research and development strategy. argenx management and scientific leadership will be joined by...
JDE Peet’s share buyback periodic update August 18, 2025 PRESS RELEASEAmsterdam, August 18, 2025JDE Peet’s (EURONEXT: JDEP), the world’s leading pure-play coffee company, today announced that it has repurchased 247,873 shares in the period from August 11, 2025 up to and including August 15, 2025. The shares were repurchased at an average price of EUR 26.03 per share for a total consideration of EUR 6.5 million. These repurchases were made as part of the EUR 250 million share buyback programme . The total number of shares repurchased under this programme to date is 5,247,069 ordinary shar...
argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis Seles speaks out about her diagnosis with MG, a chronic autoimmune disease that causes muscle weakness, which can be severe and significantly impact daily life Partnership with Seles will highlight the ‘Go for Greater’ MG patient support initiative at the 2025 U.S. Open Tennis Championships August 12, 2025 6:45 AM EDT Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today ...
JDE Peet’s share buyback periodic update August 11, 2025 PRESS RELEASEAmsterdam, August 11, 2025JDE Peet’s (EURONEXT: JDEP), the world’s leading pure-play coffee company, today announced that it has repurchased 167,402 shares in the period from August 4, 2025 up to and including August 8, 2025. The shares were repurchased at an average price of EUR 25.77 per share for a total consideration of EUR 4.3 million. These repurchases were made as part of the EUR 250 million share buyback programme . The total number of shares repurchased under this programme to date is 4,999,196 ordinary shares...
Following argenx' 2Q25 results with Vyvgart sales coming in at $ 949m, and beating CSS by 10%, we update our model, upping our Vyvgart sales estimates for FY25 to $ 3.98b (from $ 3.61b, Visible Alpha CSS: $ 3.97b). We factor in potential competition from IMAAVY (J&J), though we continue to see Vyvgart as the better product, and model approx. 12% q/q growth for 3Q25 and 4Q25. Additionally, we slightly tweak our CIDP numbers bringing us to higher peak sales ($ 4.22b vs. $ 3.76b). All in all, our t...
Last week Wednesday, JDE Peet's surprised with a strong set of 1H25 results, with the vol/mix increasing 1.0% despite a significant price increase of 21.5%. While the vol/mix effect was positively impacted by around 2-3% from customers pre-buying ahead of further anticipated price hikes, the underlying price elasticity remains resilient. This reconfirms coffee's positioning as a staple good. While price elasticity is expected to slightly deteriorate in 2H25, it should remain at healthy levels. A...
JDE Peet’s share buyback periodic update August 4, 2025 PRESS RELEASEAmsterdam, August 4, 2025JDE Peet’s (EURONEXT: JDEP), the world’s leading pure-play coffee company, today announced that it has repurchased 102,859 shares in the period from July 28, 2025 up to and including August 1, 2025. The shares were repurchased at an average price of EUR 24.10 per share for a total consideration of EUR 2.5 million. These repurchases were made as part of the EUR 250 million share buyback programme . The total number of shares repurchased under this programme to date is 4,831,794 ordinary shares fo...
argenx reported 1H25 results today, with Vyvgart sales showing a solid CSS beat. In this note you can find our main takeaways from the conference call. ARGX-119 phase 3 in CMS - argenx emphasized that they currently have 3 assets in phase 3 development with the advancement of ARGX-119 to phase 3 in Congenital Myasthenic Syndrome (CMS). ARGX-119 targets MuSK in the neuromuscular junction and is advanced in CMS, an ultra-rare disease. This allows for a small trial with dense monitoring of patients...
2Q'25 vs. 2Q'24 Results Sales: € 1.628 Bn (+4.6% vs. +4.4% BS(e) and +5.3% consensus); EBITDA: € 648.0 M (+4.3% vs. +2.8% BS(e) and +3.3% consensus); 1H'25 vs. 1H'24 Results Sales: € 3.26 Bn (+6.8% vs. +6.7% BS(e) and +7.1% consensus); EBITDA: € 1.276 Bn (+6.1% vs. +5.3% BS(e) and +5.5% consensus);
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.